Last reviewed · How we verify

NCT06551857: CaSPiN

The Effect of Cancer Treatments on Speech Perception in Noise, Cognition, and Hearing-Related Quality of Life

Recruiting now Last updated 16 April 2025
What this trial tests

trial testing Chemotherapy, chemoradiation, radiation therapy in Cancer in 250 participants. Currently enrolling.

Timeline
2 October 2024
Primary endpoint
31 December 2029
31 December 2030

Quick facts

Lead sponsorTurku University Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment250
Start date2 October 2024
Primary completion31 December 2029
Estimated completion31 December 2030
Sites1 location across Finland

Drugs / interventions tested

Conditions studied

Sponsor

Turku University Hospital

Who can join

Adults 18 to 75, any sex, with Cancer or Hearing Loss Ototoxic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will assess the effect of cancer treatments on speech perception in noise, cognition, and hearing-related quality of life by monitoring 200 cancer patients receiving standard care for their underlying malignancy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Turku University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06551857.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing